Terns Pharmaceuticals Inc (TERN) Stock Price, Quote & News

Company Profile

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1/2 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced metabolic stability and liver distribution that is in Phas...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 525 5535

Fax: 650 275 4254

Website: www.ternspharma.com

Address:

1065 East Hillsdale Boulevard, Suite 100, Foster City, United States

OMillionaires Sep. 11 at 8:42 PM

$CRBP - CB1 vs. GLP1 but my $TERN was bought out for $6.7 billion $CRBP stock price/valuation: At $25 a share $466 mil company At $50 a share $933 mil company at $100 a share $1.867 billion At $150 a share $2.8 billion

0 · Reply

et1000 Sep. 9 at 10:41 PM

$TERN lets go 100 ?

0 · Reply

55X_ROI_Q1_2026 Sep. 8 at 12:43 AM

$SLS $TERN $GILD once again to drive this point home - SLS009 Phase 2 Expansion Data Published at ASH in DEC for AML-MR patients - the most dire AML Prognosis - WAS BETTER than the $FTSV MAGRO PH1B AML-MR Data published at ASH, that $GILD Bought for $4.9B ... JUST THE SECONDARY SLS009 ASSET is ALREADY WORTH 2x 3x the current SHORT Rigged Market Cap --- right now --- With PIVOTAL, RANDOMIZED Dual ARM - FDA GREEN Light Data Incoming NEXT Quarter - in Q4. List of FDA Approved drugs based on P1/2 Data: 009 is next.

0 · Reply

55X_ROI_Q1_2026 Sep. 7 at 9:59 PM

$SLS 2 Quick Points: 1.) SLS 009 is already worth 2x 3x the current Short Rigged $2.7B Mcap - based on the $TERN $FTSV direct comps. $GILD bought Magro for $4.9B based on PH1b AML-MR Data that was NOT As good as the SLS009 PH2 AML-MR Data PUBLISHED At ASH in DEC. and the SLS009 ONGOING - Dual ARM, Randomized - PIVOTAL Trial w FDA Green light data DUE NEXT Q - in Q4 - at the FDA Request. 2.) Gps is Golden -- you may not know, but smart money does - and the ONLY REAL Question is - WHAT IS GPS WORTH ??? https://www.reddit.com/r/sellasLifescience/s/FCS5ujRm9T

0 · Reply

55X_ROI_Q1_2026 Sep. 5 at 6:40 PM

$SLS It IS ... @Duncan74 Just the secondary SLS Asset - SLS009 is already worth 2x 3x the current SLS Market Value - $TERN Ph1 KINASE INHIBITOR Data was bought for $6.7B $GILD Bought Magrolimab $FTSV for $5B based on Phase 1 AML-MR that not as Good a SLS009 PH2 AML-MR Data Already Published at ASH. 009 Currently in PH2 Expansion Dual Arm - Randomized - Pivotal Trial, at the Request of the FDA - for AML-MR Patients - MR the most DIRE AML Prognoses - with Results due Next Quarter --- CR and MRD+ OS. SLS009 offers all SLS Investors a worse case investment Scenario with a 2x 3x ROI --- the dark side of Midnight is a 2x 3x UPSIDE. https://www.biospace.com/deals/merck-to-buy-terns-unprecedented-leukemia-drug-for-6-7b-as-keytruda-cliff-looms

0 · Reply

55X_ROI_Q1_2026 Sep. 3 at 4:37 PM

$SLS $GILD SLS009 CURRENT TRUE Value / based on Market Comps $TERN $FTSV Prior P2 Published Data, 4x OS Advantage Pristine Safety Profile for Next Gen Kinase Inhibitor - ONGOING - RANDOMIZED - DUAL ARM PIVOTAL Phase 2B Expansion trial for AML-MR patients, the most dire of AML Prognosis -with PIVOTAL CR/OS FDA Green Light data incoming Next Quarter. <- 009 Current Value 2x 3x the $2.7B mcap, gives every SLS Investor a Pure 2,500% + Free Roll on Imminent GPS Results. Share Price will be $25-$30 on the 80th EVENT PR. Mark This Post.

1 · Reply

TheRealiSwag Aug. 17 at 5:44 PM

$KYTX is a hidden gem folks. There are many "under the radar" small cap bio's that warrant much more attention. KYTX is certainly one of them after a very strong quarterly update last week. Several strong catalyts on the docket next two months here. Buying most dips. $ELVN $CRVS $TERN have been others that have proved extremely successful. 🔥🔥🔥

0 · Reply

BioRich Aug. 8 at 2:22 PM

$DFTX locked and loaded. Had two orders go through by accident. Last time I did that it was with $TERN and that worked really well. Cheers!

0 · Reply

BIOTECH_GURU Jul. 30 at 1:26 PM

$ALMS $TERN Lets see if $EYPT can deliver. I expect 3x from here by the time the data is announced.

1 · Reply

YouVSYou Jul. 30 at 12:18 PM

$ALT chart in tact Key bounce spot is 2.81/2.87 daily 2.69/2.92 What happened to baby $TERN

1 · Reply

TERN Awarded $11.26 Million U.S. Army Contract to Deploy Next Generation Positioning, Navigation, and Vehicle Readiness Systems

May 5, 2026, 8:45 AM EDT - 4 months ago

Merck Completes Acquisition of Terns Pharmaceuticals, Inc.

MRK

Apr 27, 2026, 8:05 AM EDT - 4 months ago

Terns Pharmaceuticals Announces FDA Breakthrough Therapy Designation Granted to TERN-701 for Certain Patients with Chronic Myeloid Leukemia

Apr 24, 2026, 6:45 AM EDT - 4 months ago

Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.

MRK

Apr 15, 2026, 7:59 AM EDT - 5 months ago

Are TERN, SLNO, WSR Obtaining Fair Deals for their Shareholders?

SLNO WSR

Apr 7, 2026, 9:00 AM EDT - 5 months ago

Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.

MRK

Apr 2, 2026, 4:05 PM EDT - 5 months ago

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

Mar 30, 2026, 7:00 AM EDT - 5 months ago

Terns Pharmaceuticals Annual report: Q4 2025

Mar 25, 2026, 8:00 AM EDT - 5 months ago

Terns Pharmaceuticals Transcript: M&A announcement

Mar 25, 2026, 8:00 AM EDT - 5 months ago

Terns Pharmaceuticals Slides: M&A announcement

Mar 25, 2026, 8:00 AM EDT - 5 months ago

Terns Pharmaceuticals Press release: M&A announcement

Mar 25, 2026, 7:14 AM EDT - 5 months ago

Merck to buy Terns Pharmaceuticals for $6.7 billion to boost cancer pipeline

MRK

Mar 25, 2026, 6:51 AM EDT - 5 months ago

Merck boosts cancer portfolio with $6.7 billion buyout of Terns Pharma

MRK

Mar 25, 2026, 6:49 AM EDT - 5 months ago

Merck Reaches Nearly $6 Billion Deal for Cancer Biotech Terns

MRK

Mar 25, 2026, 6:48 AM EDT - 5 months ago

Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)

MRK

Mar 24, 2026, 9:14 PM EDT - 5 months ago

Merck nears $6 billion all-cash deal to buy Terns Pharma, FT reports

MRK

Mar 11, 2026, 9:00 AM EDT - 6 months ago

Terns Pharmaceuticals Transcript: The Citizens Life Sciences Conference 2026

Mar 9, 2026, 1:40 PM EDT - 6 months ago

Terns Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

Mar 2, 2026, 3:50 PM EST - 6 months ago

Terns Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Feb 25, 2026, 4:05 PM EST - 6 months ago

Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences

Jan 22, 2026, 10:26 AM EST - 7 months ago

These 20 stocks are strong choices for momentum investors

BE CELC COGT FBYD FRGE INBX KOD

Jan 12, 2026, 6:45 PM EST - 8 months ago

Terns Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 6:45 PM EST - 8 months ago

Terns Pharmaceuticals Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 7:00 AM EST - 8 months ago

Terns Pharmaceuticals Slides: Corporate presentation

Jan 7, 2026, 4:05 PM EST - 8 months ago

Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare Conference

Dec 15, 2025, 6:31 PM EST - 9 months ago

Terns CEO Amy Burroughs talks cancer drug trial win

Dec 11, 2025, 4:05 PM EST - 9 months ago

Terns Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Dec 9, 2025, 11:30 PM EST - 9 months ago

Terns Announces Pricing of Upsized $650 Million Public Offering

Dec 9, 2025, 3:31 PM EST - 9 months ago

Cancer Study Buoys These Small Biotechs

ACLX LEGN

Dec 9, 2025, 6:12 AM EST - 9 months ago

Terns Announces Proposed Public Offering

Dec 8, 2025, 4:30 PM EST - 9 months ago

Terns Pharmaceuticals Transcript: Study Update

Dec 8, 2025, 4:30 PM EST - 9 months ago

Terns Pharmaceuticals Press release: Study Update

Dec 8, 2025, 4:30 PM EST - 9 months ago

Terns Pharmaceuticals Slides: Study Update

$Terns Highlights Additional Positive Phase 1 Clinical Data Supporting TERN-701's Best-in-Disease Potential in Relapsed/Refractory CML at the 67th ASH Annual Meeting$

Dec 8, 2025, 2:45 PM EST - 9 months ago

Terns Highlights Additional Positive Phase 1 Clinical Data Supporting TERN-701's Best-in-Disease Potential in Relapsed/Refractory CML at the 67th ASH Annual Meeting

Nov 17, 2025, 11:30 AM EST - 9 months ago

Terns Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025

Nov 14, 2025, 4:05 PM EST - 10 months ago

Terns Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London

Nov 10, 2025, 4:05 PM EST - 10 months ago

Terns Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

Nov 10, 2025, 4:00 PM EST - 10 months ago

Terns Pharmaceuticals Quarterly report: Q3 2025

Nov 10, 2025, 4:00 PM EST - 10 months ago

Terns Pharmaceuticals Earnings release: Q3 2025

$Terns Announces Abstract with Positive Clinical Data for TERN-701 in Relapsed/Refractory CML Selected for Oral Presentation at 67th ASH Annual Meeting$

Nov 3, 2025, 9:05 AM EST - 10 months ago

Terns Announces Abstract with Positive Clinical Data for TERN-701 in Relapsed/Refractory CML Selected for Oral Presentation at 67th ASH Annual Meeting

Oct 21, 2025, 4:56 PM EDT - 10 months ago

Terns Pharma ends obesity drug program after mid-stage trial data

Oct 21, 2025, 4:05 PM EDT - 10 months ago

Terns Pharmaceuticals Reports Topline 12-week Data from its Phase 2 Trial Evaluating Oral GLP-1 Receptor Agonist TERN-601 in Obesity

Sep 3, 2025, 4:30 PM EDT - 1 year ago

Terns Pharmaceuticals Transcript: Study Update

Sep 3, 2025, 4:30 PM EDT - 1 year ago

Terns Pharmaceuticals Slides: Study Update

Aug 21, 2025, 4:05 PM EDT - 1 year ago

Terns Pharmaceuticals to Host an Educational Webinar on TERN-701 for Investors in Advance of Phase 1 Data Expected in Fourth Quarter 2025

Aug 5, 2025, 4:05 PM EDT - 1 year ago

Terns Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Aug 5, 2025, 4:00 PM EDT - 1 year ago

Terns Pharmaceuticals Quarterly report: Q2 2025

Aug 5, 2025, 4:00 PM EDT - 1 year ago

Terns Pharmaceuticals Earnings release: Q2 2025

Jun 23, 2025, 4:07 PM EDT - 1 year ago

Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions

Jun 9, 2025, 4:00 PM EDT - 1 year ago

Terns Pharmaceuticals Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 6, 2025, 7:00 AM EDT - 1 year ago

Terns Pharmaceuticals Slides: Corporate Presentation

Jun 5, 2025, 11:05 AM EDT - 1 year ago

Terns Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025

May 29, 2025, 4:05 PM EDT - 1 year ago

Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences

May 14, 2025, 9:30 AM EDT - 1 year ago

Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701

May 8, 2025, 4:05 PM EDT - 1 year ago

Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

May 8, 2025, 4:00 PM EDT - 1 year ago

Terns Pharmaceuticals Earnings release: Q1 2025

May 8, 2025, 4:00 PM EDT - 1 year ago

Terns Pharmaceuticals Quarterly report: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Terns Pharmaceuticals Registration statement: Registration Filing

May 7, 2025, 2:30 PM EDT - 1 year ago

Terns Pharmaceuticals Transcript: The Citizens JMP Life Sciences Conference 2025

Apr 30, 2025, 4:05 PM EDT - 1 year ago

Terns Pharmaceuticals to Participate in The Citizens Life Sciences Conference

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Terns Pharmaceuticals Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Terns Pharmaceuticals Proxy statement: Proxy Filing

Apr 2, 2025, 4:05 PM EDT - 1 year ago

Terns Pharmaceuticals Reports Inducement Grant to New Employees Under Nasdaq Listing Rule 5635(C)(4)

Mar 20, 2025, 4:05 PM EDT - 1 year ago

Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

Mar 20, 2025, 4:00 PM EDT - 1 year ago

Terns Pharmaceuticals Earnings release: Q4 2024

Mar 20, 2025, 4:00 PM EDT - 1 year ago

Terns Pharmaceuticals Annual report: Q4 2024

Mar 4, 2025, 2:30 PM EST - 1 year ago

Terns Pharmaceuticals Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 26, 2025, 4:05 PM EST - 1 year ago

Terns Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(C)(4)

Feb 25, 2025, 8:05 AM EST - 1 year ago

Terns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th Annual Healthcare Conference

Feb 24, 2025, 4:05 PM EST - 1 year ago

Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer

Feb 20, 2025, 4:05 PM EST - 1 year ago

Terns Pharmaceuticals Appoints Robert Azelby to Board of Directors

Feb 12, 2025, 4:00 PM EST - 1 year ago

Terns Pharmaceuticals Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 5, 2025, 4:05 PM EST - 1 year ago

Terns Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 3, 2025, 4:05 PM EST - 1 year ago

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

Jan 15, 2025, 7:30 PM EST - 1 year ago

Terns Pharmaceuticals Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

Terns Pharmaceuticals Slides: FY 2025

Jan 8, 2025, 4:05 PM EST - 1 year ago

Terns Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference

Dec 4, 2024, 1:18 PM EST - 1 year ago

Terns's stock soars as analysts cheer leukemia data — and predict more gains

Dec 3, 2024, 8:01 AM EST - 1 year ago

Terns Pharma broadens beyond obesity drugs with upbeat data in leukemia trial

Dec 3, 2024, 8:00 AM EST - 1 year ago

Terns Pharmaceuticals Transcript: Study Result

Dec 3, 2024, 8:00 AM EST - 1 year ago

Terns Pharmaceuticals Press release: Study Result

Dec 3, 2024, 8:00 AM EST - 1 year ago

Terns Pharmaceuticals Slides: Study Result

Nov 19, 2024, 12:00 PM EST - 1 year ago

Terns Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2024

Nov 18, 2024, 4:05 PM EST - 1 year ago

Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors

Nov 15, 2024, 11:19 AM EST - 1 year ago

RFK Jr. is not a fan of weight-loss drugs or vaccines. Stocks are tanking.

AMGN LLY NVO VKTX

OMillionaires Sep. 11 at 8:42 PM

0 · Reply

et1000 Sep. 9 at 10:41 PM

$TERN lets go 100 ?

0 · Reply

55X_ROI_Q1_2026 Sep. 8 at 12:43 AM

0 · Reply

55X_ROI_Q1_2026 Sep. 7 at 9:59 PM

0 · Reply

55X_ROI_Q1_2026 Sep. 5 at 6:40 PM

0 · Reply

55X_ROI_Q1_2026 Sep. 3 at 4:37 PM

1 · Reply

TheRealiSwag Aug. 17 at 5:44 PM

0 · Reply

BioRich Aug. 8 at 2:22 PM

$DFTX locked and loaded. Had two orders go through by accident. Last time I did that it was with $TERN and that worked really well. Cheers!

0 · Reply

BIOTECH_GURU Jul. 30 at 1:26 PM

$ALMS $TERN Lets see if $EYPT can deliver. I expect 3x from here by the time the data is announced.

1 · Reply

YouVSYou Jul. 30 at 12:18 PM

$ALT chart in tact Key bounce spot is 2.81/2.87 daily 2.69/2.92 What happened to baby $TERN

1 · Reply

BostonDave Jul. 24 at 10:07 AM

$ALT $APGE $FOLD $TECH $TERN

0 · Reply

BuddyBoy6975 Jul. 24 at 1:29 AM

$ALT $APGE $FOLD $TECH $TERN So, in your Tern chart, short interest increased over a 6 month period by 1.5-2.5 times its SI 6 months earlier. Wow. Then hit Not fairy tale gobbledygook. Legitimate. Market. Analysis. 👏👏👏👏👏👏👏👏👏👏

0 · Reply

TradeSun Jul. 23 at 5:49 PM

$ALT $APGE $FOLD $TECH Short interest of $TERN kept growing and were running into Merck s BO- Offer on March 25 😉👇

1 · Reply

DidYouReadThis Jul. 21 at 5:04 PM

$PIPR $BMO $TERN $WAVE

0 · Reply

StockMktGuru Jul. 11 at 5:09 PM

$ALT It is what it is, current SP means nothing. Check where $VKTX and $TERN have been in the past $3.X at sometime for them would have been god sent. Frustrating but hang in here, things can change in a hurry.

0 · Reply

BIOTECH_GURU Jul. 9 at 3:23 AM

$TERN $ALMS $PRME $ALT $CAPR Alright folks. You saw AlMS, TERN and CApR MAKE WILD RUNS IN 8 MONTHS. get ready for the next runs. $PRME Just formed a golden cross. Won huge legal battle which had a lot of overhang and drove price from upper teens to below $3. Continues to be the highest asymetric play in gene editing as the technology is the cleanest. In human proof of concept is already proven and published. This will make those with high conviction big gains. $ALT all the waiting will be paying off within the next 6 months. $CAPR dropped back down to let me buy the dip. 60 dollars PT. Nfa Gltya.

0 · Reply

Layne_Thomas_Staley Jul. 7 at 4:22 PM

$GANX $MRK Bought $TERN after the company pivoted away from crowded GLP weight loss land into a groundbreaking cancer drug. In microcap bio, you CANNOT BE LATE TO THE GAME. Even if a company develops a superior product, it's not like you can walk into a store and buy it off a shelf. The bottleneck is BULLISH FOR A FIRST MOVER.

0 · Reply

Layne_Thomas_Staley Jul. 7 at 4:18 PM

$GANX Nice recovery so far... Microcap bio can be brutal. It also can be your $TERN for the generational wealth

0 · Reply

shopno Jun. 30 at 12:16 AM

$SLS +1. everyone should check $TERN fabulous 2,600% ride from $2 to $53 just in 1 year! TERN is very relevant, as it's for CML and got acquired for $6.7B with early stage data. BO premium was almost absent telling everyone that it's NOT WISE to get late on-board, if you look for big reward at BO. Some of my calls, for example, are > 10x just within a few months! Check the historical $TERN price here -- on 4/8/2025 price was $2.05, and on 3/30/2026 price was $52.88! $SLS to meet & possibly beat it with blowout GPS readout! https://www.macrotrends.net/stocks/charts/TERN/terns-pharmaceuticals/stock-price-history

0 · Reply

BioRich Jun. 16 at 9:11 PM

$CRMD Quick look over at the gainers for today and I saw this grouping. How many Buyouts or deals did we have in this group? Good lord. Will $CRMD be added to that distinguished list? I think so. For fun, the 2 picks above the screen grab was $AKRO, one below was $NUVL. $TERN? $VRNA? Some real life changes in here. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!

1 · Reply

BIOTECH_GURU Jun. 16 at 1:16 PM

$SLS blah blah blah. Bears came out agains $CAPR at $7.X Came out against $REPL at $3.X Came out agains $TERN at $7.X The science will dictate where we go with $SLS. The harder they short the bigger the potential to launch 10-20x

1 · Reply

BIOTECH_GURU Jun. 9 at 4:06 AM

$ALMS $TERN $GPCR smart people follow the money.

0 · Reply

Market Cap	6.12B
Revenue (ttm)	0.00
Net Income (ttm)	-96.21M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	6,347,000
Avg Vol	6,722,514
Day's Range	N/A - N/A
Shares Out	115.52M
Stochastic %K	85%
Beta	-0.37
Analysts	Hold
Price Target	$53.00